Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Virus-infected cells presenting cytomegalovirus (CMV) antigens are host cells that have been infected by human cytomegalovirus and display viral peptides on their surface, primarily via major histocompatibility complex (MHC) molecules. These presented antigens are recognized by the immune system, particularly T cells, which mount a response to control or eliminate the infection. The most frequently recognized CMV proteins include Glycoprotein B (gB) and Phosphoprotein 65 (pp65), which serve as dominant targets for both antibody responses and cellular immunity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Virus-infected cell presenting cytomegalovirus antigens (CMV-infected cell).